Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 8;57(6):588.
doi: 10.3390/medicina57060588.

Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI

Aydin Rodi Tosu  1 , Muhsin Kalyoncuoglu  1 , Halil İbrahim Biter  1 , Sinem Cakal  1 , Murat Selcuk  2 , Tufan Çinar  2 , Erdal Belen  1 , Mehmet Mustafa Can  1
Affiliations

Prognostic Value of Systemic Immune-Inflammation Index for Major Adverse Cardiac Events and Mortality in Severe Aortic Stenosis Patients after TAVI

Aydin Rodi Tosu et al. Medicina (Kaunas). .

Abstract

Background and objectives: In this study, we aimed to evaluate whether the systemic immune-inflammation index (SII) has a prognostic value for major adverse cardiac events (MACEs), including stroke, re-hospitalization, and short-term all-cause mortality at 6 months, in aortic stenosis (AS) patients who underwent transcatheter aortic valve implantation (TAVI). Materials and Methods: A total of 120 patients who underwent TAVI due to severe AS were retrospectively included in our study. The main outcome of the study was MACEs and short-term all-cause mortality at 6 months. Results: The SII was found to be higher in TAVI patients who developed MACEs than in those who did not develop them. Multivariate Cox regression analysis revealed that the SII (HR: 1.002, 95%CI: 1.001-1.003, p < 0.01) was an independent predictor of MACEs in AS patients after TAVI. The optimal value of the SII for MACEs in AS patients following TAVI was >1.056 with 94% sensitivity and 96% specificity (AUC (the area under the curve): 0.960, p < 0.01). We noted that the AUC value of SII in predicting MACEs was significantly higher than the AUC value of the C-reactive protein (AUC: 0.960 vs. AUC: 0.714, respectively). Conclusions: This is the first study to show that high pre-procedural SII may have a predictive value for MACEs and short-term mortality in AS patients undergoing TAVI.

Keywords: SII; TAVI; inflammation; major adverse cardiac events; mortality.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they do not have a conflict of interest.

Figures

Figure 1
Figure 1
A receiving operating characteristics curve analysis comparison of the systemic immune-inflammation index (SII) and C-reactive protein for major adverse cardiac events (MACEs), including stroke, re-hospitalization, and short-term all-cause mortality at 6 months. CRP: C-reactive protein; AUC: the area under the curve.
Figure 2
Figure 2
The Kaplan–Meier plots of survival curves of patients with low (blue line) and high systemic immune-inflammation index (SII) (green line).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eveborn G.W., Schirmer H., Heggelund G., Lundet P., Ralsmussen K. The evolving epidemiology of valvular aortic stenosis. the Tromsø study. Heart. 2013;99:396–400. doi: 10.1136/heartjnl-2012-302265. - DOI - PubMed
    1. Galante A., Pietroiusti A., Vellini M., Piccolo P., Possati G., De Bonis M., Grillo R.L., Fontana C., Favalli C. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J. Am. Coll. Cardiol. 2001;38:1078–1082. doi: 10.1016/S0735-1097(01)01484-X. - DOI - PubMed
    1. Masson J.B., Kovac J., Schuler G., Ye J., Cheung A., Kapadia S., Tuzcu M.E., Kodali S., Leon M.B., Webb J.G. Transcatheter aortic valve implantation: Review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc. Interv. 2009;2:811–820. doi: 10.1016/j.jcin.2009.07.005. - DOI - PubMed
    1. Toutouzas K., Stathogiannis K., Latsios G., Synetos A., Drakopoulou M., Penesopoulou V., Michelongona A., Tsiamis E., Tousoulis D. Biomarkers in aortic valve stenosis and their clinical significance in transcatheter aortic valve implantation. Curr. Med. Chem. 2019;26:864–872. doi: 10.2174/0929867324666170727110241. - DOI - PubMed
    1. Takagi H., Kuno T., Hari Y., Nakashima K., Yokoyama Y., Ueyama H., Ando T., ALICE (All-Literature Investigation of Cardiovascular Evidence) Group Prognostic impact of baseline C-reactive protein levels on mortality after transcatheter aortic valve implantation. J. Card. Surg. 2020;35:974–980. doi: 10.1111/jocs.14499. - DOI - PubMed